CCM
IMRX icon

CAAS Capital Management’s Immuneering IMRX Stock Holding History

CAAS Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-40,000
Closed -$1.06M – 947
2021
Q3 		$1.06M Buy
+40,000
New +$1.07M 0.02% 469

Other funds holding IMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAAS Capital Management's IMRX Position: Q4 2021 in Review

CAAS Capital Management sold out of Immuneering (IMRX) in Q4 2021, closing a stake of 40,000 shares — an estimated $1.06M sold.

CAAS Capital Management first reported a position in IMRX in Q3 2021 and held it in 1 quarter. The position peaked at $1.06M in Q3 2021. 37 funds tracked by Wall St. Rank hold IMRX as of Q4 2021.

  • CAAS Capital Management reported no remaining Immuneering position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 40,000 Immuneering shares in Q4 2021, an estimated $1.06M.
  • CAAS Capital Management first reported a position in Immuneering in Q3 2021 and held it in 1 quarter.
  • CAAS Capital Management's Immuneering position peaked at $1.06M in Q3 2021.
  • 37 funds tracked by Wall St. Rank held Immuneering as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.